darunavir has been researched along with niacin in 2 studies
Studies (darunavir) | Trials (darunavir) | Recent Studies (post-2010) (darunavir) | Studies (niacin) | Trials (niacin) | Recent Studies (post-2010) (niacin) |
---|---|---|---|---|---|
1,148 | 224 | 780 | 11,974 | 462 | 1,488 |
Protein | Taxonomy | darunavir (IC50) | niacin (IC50) |
---|---|---|---|
Cholesteryl ester transfer protein | Homo sapiens (human) | 0.14 | |
Cytochrome P450 2C9 | Homo sapiens (human) | 0.14 | |
Hydroxycarboxylic acid receptor 2 | Homo sapiens (human) | 0.1726 | |
Hydroxycarboxylic acid receptor 2 | Mus musculus (house mouse) | 0.14 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Bellistrì, GM; Cannizzo, ES; d'Arminio Monforte, A; Garau, M; Mancusi, D; Marchetti, G; Savoldi, A; Termini, R; Tincati, C | 1 |
1 review(s) available for darunavir and niacin
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for darunavir and niacin
Article | Year |
---|---|
T-cell phenotype and function following a first cART regimen containing either a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor in HIV-infected late presenters: results from a retrospective, ex vivo study.
Topics: Adult; Anti-HIV Agents; Ascorbic Acid; Darunavir; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Immunophenotyping; Male; Middle Aged; Niacin; Pyridoxine; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; T-Lymphocytes; Zinc Compounds | 2016 |